Method for constructing apolipoprotein A-V gene knockout rabbit and constructed gene knockout rabbit

The CRISPR/Cas9 system effectively constructs an ApoA-V knockout rabbit model, addressing the limitations of mouse models by providing a more accurate animal model for studying ApoA-V's role in triglyceride metabolism and atherosclerosis, facilitating drug development and mechanistic research.

CN119061013APending Publication Date: 2024-12-03WUYI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411335496.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-24
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The lack of a suitable animal model hinders the understanding of the role of apolipoprotein AV (ApoA-V) in the regulation of triglyceride metabolism and its association with cardiovascular diseases such as atherosclerosis, as existing studies in mice do not accurately replicate human hypertriglyceridemia or provide clear insights into the mechanism of ApoA-V in atherosclerosis.

Method used

A CRISPR/Cas9 system is used to knockout the apolipoprotein AV gene in rabbits, specifically utilizing a designed sgRNA to target and edit the ApoA-V gene, resulting in a rabbit model that accurately reflects human lipid metabolism and atherosclerosis characteristics.

Benefits of technology

The ApoA-V knockout rabbit model provides a more suitable animal model for studying the relationship between ApoA-V and atherosclerosis, enabling deeper exploration of hypertriglyceridemia and atherosclerosis mechanisms, and serves as a tool for drug screening and translational medicine research.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005058133460000062
    Figure BDA0005058133460000062
  • Figure BDA0005058133460000071
    Figure BDA0005058133460000071
  • Figure BDA0005058133460000072
    Figure BDA0005058133460000072
Patent Text Reader

Abstract

The invention discloses a method for constructing an apolipoprotein A-V gene knockout rabbit and the constructed gene knockout rabbit. The ApoA-V gene knockout rabbit model constructed by the scheme provided by the invention can be applied to exploration of various target spots of hyperlipidemia and atherosclerosis, belongs to one part of transformational medicine research, and provides a new theoretical basis and a more suitable animal model for preventing and treating hyperlipidemia such as hypertriglyceridemia and atherosclerosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and particularly relates to a method for constructing apolipoprotein AV gene knockout rabbits and the constructed gene knockout rabbits. Background Art

[0002] Cardiovascular diseases with atherosclerosis as the main pathological basis are the number one killer that endangers human health. It is currently known that hypertriglyceridemia is an independent risk factor for atherosclerosis. Disturbance in the metabolism of triglyceride-rich lipoproteins (TRLs) is the main cause of hypertriglyceridemia. However, the specific mechanism of TRLs metabolism has not been fully studied, including apolipoprotein AV (ApoA-V) involved in the regulation of TRLs metabolism. Related studies have shown that ApoA-V is mainly present on TRLs and is one of the important factors regulating triglyceride (TG) metabolism. Large-scale genetic studies have shown that loss of function caused by mutations in the human ApoA-V gene is associated with hypertriglyceridemia, and suggest that it may increase the incidence of cardiovascular events such as coronary heart disease and myocardial infarction. However, how ApoA-V plays a role in the occurrence and development of atherosclerosis has not been clarified, one of the reasons being the lack of a suitable animal model.

[0003] ApoA-V is the last member of the apolipoprotein APOA1 / APOC3 / APOA4 / APOA5 gene cluster on human chromosome 11 and was first discovered in 2001. ApoA-V is produced in the liver and is mainly present on TRLs, including chylomicrons and very low-density lipoproteins (VLDL). Although the plasma concentration of ApoA-V in normal people is only 100μg / dL, ApoA-V plays an important role in lipoprotein metabolism. ApoA-V is considered to be an important factor in regulating plasma TG levels. As an activator of lipoprotein lipase (LPL), which is crucial in TG catabolism, ApoA-V reduces plasma TG levels by enhancing the decomposition of TRLs. At the same time, ApoA-V can inhibit the synthesis and secretion of VLDL in the liver, and reduce the content of TG in plasma by promoting the liver's uptake of TRLs residues and other mechanisms. In addition, ApoA-V may participate in the metabolism of lipids and lipoproteins by binding to low-density lipoprotein receptor (LDLR) and low-density lipoprotein receptor-related protein (LRP) as a ligand.

[0004] Human ApoA-V gene mutations show obvious hypertriglyceridemia, and the level of TG in plasma can reach about 6000 mg / dL, and is positively correlated with the risk of coronary heart disease. Epidemiological statistical analysis shows that ApoA-V gene mutation is the second highest risk gene for myocardial infarction besides LDLR mutation. ApoA-V mutations cause TRLs to increase by 60%, and the risk of myocardial infarction increases by 2.2 times. In addition, ApoA-V gene polymorphisms are closely related to the occurrence of obesity and metabolic syndrome. These correlation studies provide favorable evidence for explaining the clinical significance of ApoA-V, but they cannot answer whether ApoA-V is related to the occurrence of atherosclerosis, such as whether there is a causal relationship. Therefore, an animal model is urgently needed to study the relationship between ApoA-V and atherosclerosis. Summary of the invention

[0005] The present invention aims to solve at least one of the technical problems existing in the above-mentioned prior art. To this end, the present invention provides a sgRNA.

[0006] The present invention also provides a nucleic acid molecule encoding the above sgRNA.

[0007] The present invention also provides an expression cassette, a recombinant vector or a transgenic cell line comprising the above nucleic acid molecule.

[0008] The present invention also provides a CRISPR / Cas9 system.

[0009] The present invention also provides the use of the above-mentioned sgRNA, nucleic acid molecule, expression cassette, recombinant vector or transgenic cell line or CRISPR / Cas9 system.

[0010] The invention also provides a method for constructing apolipoprotein AV gene knockout rabbit.

[0011] The invention also provides an apolipoprotein AV gene knockout rabbit.

[0012] The present invention also provides the application of the apolipoprotein AV gene knockout rabbit.

[0013] According to one aspect of the present invention, a sgRNA is provided, wherein the sequence of the sgRNA is shown in SEQ ID NO: 1 or SEQ ID NO: 2.

[0014] According to the second aspect of the present invention, a nucleic acid molecule encoding the above-mentioned sgRNA is provided.

[0015] According to the third aspect of the present invention, an expression cassette, a recombinant vector or a transgenic cell comprising the above nucleic acid molecule is provided.

[0016] In some embodiments of the present invention, the expression cassette refers to a DNA capable of expressing the sgRNA in a host cell, and the DNA may include not only a promoter for initiating transcription of the gene encoding the sgRNA, but also a terminator for terminating transcription of the gene encoding the sgRNA.

[0017] Preferably, the expression cassette may further comprise an enhancer sequence.

[0018] According to a fourth aspect of the present invention, a CRISPR / Cas9 system is proposed, comprising the above-mentioned sgRNA.

[0019] In some embodiments of the present invention, the CRISPR / Cas9 system further comprises Cas9.

[0020] In some embodiments of the invention, the Cas9 is Cas9 mRNA.

[0021] In some embodiments of the present invention, in the CRISPR / Cas9 system, the added mass ratio of Cas9 mRNA and sgRNA is (1-5):1.

[0022] In some embodiments of the present invention, in the CRISPR / Cas9 system, the added mass ratio of Cas9 mRNA and sgRNA is (2-4):1.

[0023] According to a fifth aspect of the present invention, the use of the above-mentioned sgRNA, nucleic acid molecule, expression cassette, recombinant vector or transgenic cell line or CRISPR / Cas9 system in any of the following is proposed:

[0024] (a1) specifically recognizes the apolipoprotein AV gene;

[0025] (a2) knocking out the gene that specifically recognizes apolipoprotein AV;

[0026] (a3) constructing apolipoprotein AV gene knockout cell line;

[0027] (a4) preparing a product for constructing apolipoprotein AV gene knockout cell line;

[0028] (a5) Construction of apolipoprotein AV gene knockout rabbits;

[0029] (a6) Preparation of products for constructing apolipoprotein AV gene knockout rabbits.

[0030] In some embodiments of the present invention, the application is for purposes other than disease diagnosis and treatment.

[0031] According to a sixth aspect of the present invention, a method for constructing apolipoprotein AV gene knockout rabbits is proposed, the method comprising the following steps: using the above-mentioned CRISPR / Cas9 system to knock out the apolipoprotein AV gene in the rabbit.

[0032] In some embodiments of the present invention, the method specifically comprises the following steps:

[0033] (b1) transferring the above-mentioned CRISPR / Cas9 system into the fertilized egg of the donor rabbit to obtain a gene-edited fertilized egg;

[0034] (b2) transplanting the gene-edited fertilized egg into the uterus of a recipient rabbit to give birth to F0 generation rabbits, i.e., apolipoprotein AV gene knockout rabbits.

[0035] In some embodiments of the invention, the method of transferring comprises injection.

[0036] According to a seventh aspect of the present invention, an apolipoprotein AV gene knockout rabbit is provided, which is constructed by the above method.

[0037] According to an eighth aspect of the present invention, an application of the apolipoprotein AV gene knockout rabbit is provided, wherein the application is application in drug screening.

[0038] In some embodiments of the present invention, the drug includes a drug for treating hyperlipidemia or atherosclerosis.

[0039] In some embodiments of the present invention, the drug includes a drug for treating atherosclerotic cardiovascular disease caused by abnormal blood lipid levels.

[0040] In some embodiments of the present invention, the application is application in preparing a drug screening kit.

[0041] In some embodiments of the present invention, the application is an application in preparing a tool for studying the relationship between apolipoprotein AV gene and atherosclerosis.

[0042] In some embodiments of the present invention, the application is application in preparing a tool for studying the relationship between hyperlipidemia and atherosclerosis.

[0043] In some embodiments of the present invention, the hyperlipidemia includes at least one of hypertriglyceridemia, hypercholesterolemia and familial inherited spontaneous hyperlipidemia.

[0044] In some embodiments of the present invention, the application is application in studying the mechanism of ApoA-V in lipid metabolism.

[0045] In some embodiments of the present invention, the use is not for the purpose of diagnosis or treatment of a disease.

[0046] According to some embodiments of the present invention, there are at least the following beneficial effects:

[0047] The present invention provides an sgRNA, which can be used to specifically identify the apolipoprotein AV gene, knock out the apolipoprotein AV gene, and construct an apolipoprotein AV gene knockout rabbit; at the same time, the sgRNA provided by the present invention can efficiently cut at the apolipoprotein AV gene target site in a rabbit model, the target site activity is high, and the apolipoprotein AV gene knockout rabbit can be constructed 100%.

[0048] The ApoA-V knockout rabbit model constructed by the scheme of the present invention can be used to explore the targets of various hyperlipidemias (including hypertriglyceridemia, hypercholesterolemia and familial spontaneous hyperlipidemia) and atherosclerosis, and is part of translational medicine research, providing a new theoretical basis and a more suitable animal model for the prevention and treatment of hyperlipidemias such as hypertriglyceridemia and atherosclerosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0049] The present invention will be further described below with reference to the accompanying drawings and embodiments, wherein:

[0050] Figure 1 This is the design diagram of ApoA-V sgRNA in Example 1 of the present invention;

[0051] Figure 2 This is a technical flow chart of constructing ApoA-V gene knockout rabbits in Example 2 of the present invention;

[0052] Figure 3 This is a graph showing the results of testing sgRNA efficiency at the embryo level in Example 2 of the present invention;

[0053] Figure 4 This is a diagram of the sequencing results of the positive rabbits in Example 2 of the present invention. DETAILED DESCRIPTION

[0054] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.

[0055] Example 1

[0056] In this example, a sgRNA sequence was prepared, and the design process was as follows: Figure 1As shown in the figure, the specific design process is as follows: after searching the rabbit ApoA-V gene sequence (NCBI No.: 100328796) on the NCBI website, sgRNA is designed for the ApoA-V gene. Since ApoA-V has four transcriptional variants, sgRNA is designed on the common exon, and two sgRNA sequences are screened and designed, as follows:

[0057] sgRNA1: GTCCGCAATAATGGCAAGCT (SEQ ID NO: 1);

[0058] sgRNA2: GCTGGGTCCTATGAGCGTGC (SEQ ID NO: 2).

[0059] Example 2

[0060] This example prepares an ApoA-V gene knockout rabbit. Figure 2 As shown, effective sgRNA and Cas9 are introduced into fertilized eggs by microinjection and then transplanted into surrogate mother rabbits. After the full-term offspring are born, their genes are identified and positively edited F0 generation offspring are screened for subsequent group expansion and phenotypic analysis. The specific process is as follows:

[0061] 1. In vitro transcription of gRNA and Cas9

[0062] (1) Preparation of gRNA in vitro transcription template

[0063] First, the following primer sequences were synthesized by Guangzhou Aiji Biotechnology Co., Ltd.:

[0064] T7-F:

[0065] 5'-GGATCCTAATACGACTCACTATAGNNNNNNNNNNNNNNNNNNGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAG-3' (SEQ ID NO: 3);

[0066] T7-R:

[0067] 5'-AAAAAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCC TTATTTTAACTTGCTATTTCTAGCTCTAAAAC-3' (SEQ ID NO: 4).

[0068] The above sequence was used as primer and template, and the high-fidelity enzyme 2× Max Master Mix (Dye Plus) (Vazyme) was used for PCR amplification, and the final amplification product was the template for gRNA in vitro transcription.

[0069] The PCR amplification reaction system is shown in Table 1 below.

[0070] Table 1

[0071]

[0072] The PCR amplification reaction procedure is as follows: After the PCR reaction system is prepared, it is placed in a PCR instrument for pre-denaturation at 95°C for 3 minutes, and then maintained at 95°C for 30 seconds; the temperature is lowered to 60°C and maintained for 30 seconds to allow the primers to fully link with the template, and maintained at 72°C for 10 seconds to allow the primers to extend on the template and synthesize DNA to complete a cycle. Repeat 35 cycles to accumulate a large number of DNA fragments, maintain at 72°C for 5 minutes, and store at 4°C after completion.

[0073] After PCR amplification is completed, take out a certain amount of amplified product and perform agarose gel electrophoresis experiment. After confirming that it is a single band and the fragment size is as expected, follow the operating steps of the DNA gel recovery kit to recover and purify the DNA. After recovery, dissolve it in 20μL of RNase-free water and store it at -20℃ for later use.

[0074] (2) sgRNA in vitro transcription

[0075] The in vitro transcription of sgRNA was performed according to the operating procedures of the T7 High Efficiency RNA Synthesis Kit. The reaction system is shown in Table 2 below.

[0076] Table 2

[0077]

[0078] The reaction was placed in a PCR instrument at 37°C for 8 hours. Then 1 μL of deoxyribonuclease 1 (DNase1) was added to the above 20 μL reaction system and placed in a PCR instrument at 37°C for 15 minutes to remove the template DNA. The transcribed sgRNA product was then purified according to the operating procedures of the kit, and the concentration of the pure product was determined using NanoDrop 1000, adjusted to 150 ng / μL, and aliquoted and stored at -80°C for subsequent fertilized egg cytoplasmic injection.

[0079] (3) Cas9 mRNA in vitro transcription

[0080] The plasmid used in the present invention is addgene-41815Cas9 plasmid (referred to as spCas9 plasmid) (from Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences), and is extracted using a plasmid extraction kit (purchased from Shanghai Sangon Biotechnology Co., Ltd.), and the extracted plasmid is placed in an environment of -20°C for standby use.

[0081] First, the spCas9 plasmid was linearized, and then the linearized plasmid was used as a template to perform mMESSAGE T7 Kit and E. coli poly(A) Polymerase (NEB) were used for in vitro transcription and tailing modification. The specific reaction system is shown in Table 3 below.

[0082] Table 3

[0083]

[0084]

[0085] The reaction system was placed in a PCR instrument and reacted at 37°C for 4 hours. Then 1 μL of DNase 1 was added to the above 20 μL reaction system and placed in a PCR instrument at 37°C for 15 minutes to remove the template DNA. Subsequently, the capped in vitro transcribed Cas9 mRNA was recovered according to the above steps for processing the sgRNA transcription process.

[0086] On this basis, E. coli poly(A) Polymerase performs tailing treatment on the recovered product. The reaction system is shown in Table 4 below.

[0087] Table 4

[0088]

[0089] Then, the product was recovered and purified using RNeasy Mini Kit (Qiagen). 1 μL of the recovered product was appropriately diluted and its concentration was determined using NanoDrop 1000, and then diluted with RNase-free water, and the product was aliquoted and stored at -80°C for subsequent fertilized egg injection.

[0090] 2. Testing sgRNA efficiency at the embryo level

[0091] The oviduct of a normally fertilized female rabbit after superovulation was taken, and the fertilized embryo was flushed out with a physiological saline serum mixture (mixed with 38 mL of physiological saline and 2 mL of fetal bovine serum FBS), and the mixed Cas9 mRNA and sgRNA mixed system (5 uL system, wherein Cas9 mRNA 750 ng, sgRNA 250 ng) was injected into the fertilized embryo according to the micromanipulation technique, and the injected embryo was transferred to the embryo culture medium (the formula is shown in Table 5), and placed in an incubator at 38.5 ° C and 5% CO2 concentration for in vitro culture. After 4-5 days of culture, the embryo that developed into the blastocyst was taken, NP40 lysed (5 μL NP40 per tube, 1 embryo was added), and the lysed embryo was used as a template. After PCR amplification of the target fragment, the corresponding sequencing primer was used for sequencing.

[0092] Table 5

[0093]

[0094] ApoA5 sgRNA1 PCR Primers:

[0095] Forward: GGCCAAAGAGGACTAGGGAT (SEQ ID NO: 5); Reverse: GCTTCTGGGGTTTGGGGTTC (SEQ ID NO: 6).

[0096] Sequencing primers:

[0097] Forward: GGCCAAAGAGGACTAGGGAT(SEQ ID NO:7);

[0098] Reverse: GCTTCTGGGGTTTGGGGTTC (SEQ ID NO: 8).

[0099] ApoA5 sgRNA2 PCR Primers:

[0100] Forward: AGAATGGCGGTACACCCATG (SEQ ID NO: 9); Reverse: CGTGTAGGGCTTCAGTTGCT (SEQ ID NO: 10).

[0101] Sequencing primers:

[0102] Forward: AGAATGGCGGTACACCCATG (SEQ ID NO: 11); Reverse: CGTGTAGGGCTTCAGTTGCT (SEQ ID NO: 12).

[0103] The specific PCR reaction system is shown in Table 6 below.

[0104] Table 6

[0105]

[0106]

[0107] Specific PCR reaction procedure: place the above system in a PCR instrument and preheat at 95°C for 3 minutes, then keep at 95°C for 30 seconds, reduce the temperature to 68°C and maintain for 30 seconds to allow the primers to fully combine with the template (using gradient annealing, reducing 0.4°C each cycle), then maintain at 72°C for 30 seconds to allow the primers to extend on the template and merge DNA, repeat 35 cycles to accumulate a large number of DNA fragments, and finally maintain at 72°C for 5 minutes to allow the product to be fully extended and stored at 4°C.

[0108] The PCR amplification products were sequenced, and after sequencing, the sequencing results were compared with the rabbit ApoA-V gene map to analyze the knockout efficiency of sgRNA at the embryonic level.

[0109] The results are as follows Figure 3 As shown in the figure, it can be seen that both sgRNA1 and sgRNA2 can achieve sgRNA knockout at the embryonic level. The knockout efficiency of sgRNA1 is about 60%, and the knockout efficiency of sgRNA1 is significantly better than that of sgRNA2.

[0110] 3. Microinjection and embryo transfer

[0111] (1) Collection of fertilized eggs

[0112] Follicle stimulating hormone (FSH) was subcutaneously injected into female sexually mature New Zealand white rabbits for three consecutive days (twice a day) to promote superovulation in female rabbits. 72 hours after the first injection of FSH (injection volume of 5 units / kg), 200 IU of HCG was injected intravenously to induce ovulation. The female rabbits injected with HCG were naturally mated with male rabbits. After successful mating for 17-19 hours, the female rabbits were euthanized by overdose of anesthesia, and the oviducts were carefully removed and placed in 25 mL of HM medium (25mM HEPES, 10% fetal bovine serum in Medium 199 with Hanks's salts). Another 25 mL of HM medium was prepared to flush the embryos out of the oviduct for microinjection.

[0113] (2) Complete microinjection

[0114] Prepare a mixed system of Cas9 mRNA and sgRNA (5uL system, including 750ng Cas9 mRNA and 250ng gRNA), and then complete the microinjection operation. Culture the gene-edited fertilized eggs at 38.5°C and 5% CO2 for 1-2 hours or overnight, and select suitable fertilized embryos for transplantation.

[0115] (3) Transplanting the gene-edited fertilized embryo into the recipient rabbit

[0116] Select female rabbits over 5 months old and weighing 3-4 kg and inject carprofen (4 mg / kg) subcutaneously for induction of anesthesia. After induction of anesthesia, place the recipient rabbit on the operating table and connect it to the respiratory anesthesia machine. When the recipient rabbit breathes steadily and enters deep anesthesia, perform the operation. Tie the rabbit to the operating table, trim the hair with the lateral abdomen as the center, disinfect, cover with sterile surgical pads and fix. Make a 2-3 cm incision at the expected position of the ovary, cut the skin, fascia, muscle layer and peritoneum in turn, and carefully expose the fallopian tube. The assistant puts the embryos (10-15) into the embryo transfer tube. The operator gently pinches the fallopian tube umbrella with a small curved forceps in his left hand, and gently inserts the transplant tube from the fallopian tube umbrella with his right hand. The assistant gently moves the fallopian tube with smooth forceps to straighten it so that it can be inserted smoothly. After inserting the transplant tube 3-5 ml (inflated part) and then retreating a little, the assistant slowly injects the embryo into the fallopian tube and slowly removes the transplant tube while injecting. After the embryo injection, use forceps to hold the mesentery to raise the end of the fallopian tube umbrella, and move the embryo towards the uterus to move the embryo towards the uterus as much as possible, and carefully put the fallopian tube back into the abdominal cavity. Remove the dirty blood and other foreign objects in the abdominal cavity, count the surgical instruments, and check for intraperitoneal bleeding. Rinse with preheated sterile saline, suture the peritoneum and muscle layer continuously, sprinkle penicillin and streptomycin on the wound after the muscle layer is sutured, and then continue to suture the skin. After the end, disinfect the wound with iodine tincture. After the operation, double antibodies are injected intramuscularly, and the recipient rabbit is placed in a cage for separate feeding.

[0117] 4. Genotyping of newborn rabbits

[0118] The use of embryo transfer after pronuclear injection of fertilized eggs to impregnate the female rabbit has little effect on the gestation period, so the gestation period is the same as that of mating conception, and the birth is about 30 days after transplantation. A small piece of ear tissue of the newborn rabbit was taken, and the genomic DNA of the newborn rabbit was extracted according to the product operation steps of the blood / tissue / cell genome extraction kit of Tiangen Biochemical Technology Co., Ltd., and the identification primers (sgRNA1 PCR primer SEQ ID NO: 5, SEQ ID NO: 6; sgRNA2 PCR primer SEQ ID NO: 8, SEQID NO: 9) were used to PCR amplify the target fragment (the reaction system is shown in Table 7), and the PCR amplification primers were sequenced to detect its genotype ( Figure 4 ).

[0119] Table 7

[0120]

[0121] PCR amplification procedure: The system described in Table 6 above was placed in a PCR instrument and preheated at 95°C for 3 min, then maintained at 95°C for 30 s, the temperature was lowered to 68°C and maintained for 30 s to allow the primers to fully bind to the template (gradient annealing was used, with a decrease of 0.4°C in each cycle), then maintained at 72°C for 30 s to allow the primers to extend on the template and merge the DNA, repeated 35 cycles to allow a large number of DNA fragments to accumulate, and finally maintained at 72°C for 5 min to allow the product to be fully extended and stored at 4°C.

[0122] The results are as follows Figure 4 As shown, from Figure 4 It can be seen that the sgRNA1 and sgRNA2 prepared by the scheme of the present invention can both effectively construct apolipoprotein AV gene knockout rabbits.

[0123] Related technologies include the use of mice to construct apolipoprotein AV gene knockout animal model, but in mouse experimental studies, the relationship between ApoA-V and atherosclerosis is still uncertain. Len A. Pennacchio et al. constructed ApoA-V gene knockout mice and found that the TG of ApoA-V-deficient mice also had a slight increase (about 150 mg / dL), but failed to simulate the characteristics of human hypertriglyceridemia well, and no experimental studies related to atherosclerosis were conducted.

[0124] Although mice have numerous advantages as the main experimental animals in the field of medical research, there are certain limitations to using only mouse models to study the in vivo metabolic function of ApoA-V and atherosclerosis. For example, it is generally difficult to induce atherosclerosis in wild-type mice through a high-fat diet. ApoE knockout and LDLR knockout mice are two commonly used mouse models for atherosclerosis research after gene editing, but they are not suitable for studying coronary arteries and myocardial infarction, as well as the direct interaction between ApoA-V and ApoE, LDLR and cholesterol ester transfer protein (CETP) because mice do not have CETP. Therefore, it is urgent to provide a new apolipoprotein AV gene knockout animal model.

[0125] The uniqueness of the present invention lies in that it successfully constructed the first ApoA-V gene knockout rabbit model, which is unique both domestically and internationally. However, in the mouse model, the deletion of the ApoA-V gene failed to fully replicate the typical pathological characteristics of human hypertriglyceridemia. At the same time, the specific association mechanism between ApoA-V and atherosclerosis has yet to be revealed in the mouse model. Given that the lipid metabolism characteristics of rabbits are more similar to those of humans, using this new model, we can deeply explore the impact of reduced ApoA-V expression on the molecular mechanism of hypertriglyceridemia, as well as the function of ApoA-V in aortic atherosclerosis, which are research areas that are difficult to reach with current mouse models. Therefore, the implementation of this project is significantly innovative in terms of methods and technologies.

[0126] Rabbits have been used as animal models for atherosclerosis research for more than 100 years. They have not only revealed countless molecular mechanisms related to atherosclerosis, but also the current mainstream modern theories of atherosclerosis such as the "cholesterol theory" and "inflammatory theory" originally came from experimental studies on rabbit atherosclerosis. Rabbits and humans have similar lipoprotein metabolism characteristics, making them more suitable as animal models for human lipid metabolism research: unlike mice but the same as humans, the main lipoprotein in rabbit blood is LDL, while in mice it is HDL; mice are congenitally deficient in CETP, an important regulatory factor in lipid metabolism, while rabbits and humans both contain CETP; mouse liver has mRNA editing activity for apolipoprotein B (ApoB), so the VLDL and LDL produced by mouse liver contain both ApoB100 and ApoB48, while rabbit and human VLDL only contains ApoB100 and ApoB48 only exists in intestinal-derived chylomicrons, so the metabolic rate of VLDL / LDL in mice is much higher than that in rabbits and humans; in addition, mice are not sensitive to a high-cholesterol diet, while rabbits are sensitive to a high-cholesterol diet and are prone to developing lesions with pathological characteristics that are closer to human atherosclerosis.

[0127] The embodiments of the present invention are described in detail above in conjunction with the accompanying drawings, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.

Claims

1. A sgRNA, characterized in that The sequence of the sgRNA is shown in SEQ ID NO: 1 or SEQ ID NO:

2.

2. A nucleic acid molecule encoding the sgRNA according to claim 1.

3. An expression cassette, a recombinant vector or a transgenic cell comprising the nucleic acid molecule according to claim 2.

4. A CRISPR / Cas9 system, comprising the sgRNA according to claim 1; Preferably, the CRISPR / Cas9 system further comprises Cas9.

5. Use of the sgRNA according to claim 1, the nucleic acid molecule according to claim 2, the expression cassette, the recombinant vector or the transgenic cell according to claim 3 or the CRISPR / Cas9 system according to claim 4 in any of the following: (a1) specifically recognizes the apolipoprotein AV gene; (a2) knocking out the gene that specifically recognizes apolipoprotein AV; (a3) constructing apolipoprotein AV gene knockout cell line; (a4) preparing a product for constructing apolipoprotein AV gene knockout cell line; (a5) Construction of apolipoprotein AV gene knockout rabbits; (a6) Preparation of products for constructing apolipoprotein AV gene knockout rabbits.

6. A method for constructing apolipoprotein AV gene knockout rabbit, characterized in that: The method comprises the following steps: using the CRISPR / Cas9 system as described in claim 4 to knock out the apolipoprotein AV gene in rabbits.

7. The method according to claim 6, characterized in that The method specifically comprises the following steps: (b1) transferring the CRISPR / Cas9 system as described in claim 4 into the fertilized egg of the donor rabbit to obtain a gene-edited fertilized egg; (b2) transplanting the gene-edited fertilized egg into the uterus of a recipient rabbit to give birth to F0 generation rabbits, i.e., apolipoprotein AV gene knockout rabbits.

8. An apolipoprotein AV gene knockout rabbit, characterized in that: The method is constructed according to claim 6 or 7.

9. Use of the apolipoprotein AV gene knockout rabbit according to claim 8 in any of the following: (c1) Drug screening; (c2) preparing a drug screening kit; (c3) Preparation of tools for studying the relationship between apolipoprotein AV gene and atherosclerosis; (c4) Prepare tools to study the relationship between hyperlipidemia and atherosclerosis; (c5) To study the mechanism of apolipoprotein AV gene in lipid metabolism.

10. The use according to claim 9, characterized in that: The hyperlipidemia includes at least one of hypertriglyceridemia, hypercholesterolemia and familial hereditary spontaneous hyperlipidemia.